Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical ...
DA-1726 is a clinical-stage, long-acting dual-incretin peptide designed to mimic the naturally occurring gut hormone oxyntomodulin. By simultaneously activating GLP-1 and glucagon receptors, it aims to decrease food intake while increasing energy expenditure. It is currently in Phase 1 clinical trials with optimized titration regimens to improve weight loss, glucose control, and metabolic health.
Price Range: N/A (Clinical-stage development)
Pain Points: Suboptimal weight loss, poor glucose control, and metabolic dysfunction associated with obesity.
Solutions: Enhanced weight loss via dual-mechanism energy expenditure and appetite suppression, coupled with glucose regulation.
Target Users: Patients diagnosed with obesity and associated cardiometabolic conditions.
Supply Chain
Dong-A ST Co., Ltd. (Licensing partner)Contract manufacturing organizations (CMO)Clinical research organizations (CRO)
Vanoglipel is a first-in-class G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of gut peptides like GLP-1, GIP, and PYY. It has demonstrated efficacy in reducing hepatic steatosis, inflammation, and fibrosis in pre-clinical and Phase 2a studies, showing direct hepatic action alongside systemic glucose lowering effects.
Price Range: N/A (Clinical-stage development)
Pain Points: Liver damage, inflammation, and fibrosis in patients with metabolic dysfunction.
Solutions: Direct hepatic protection, reduction of liver fat, and improved systemic metabolic and glucose control.
Target Users: Patients with MASH and associated metabolic liver diseases.
Supply Chain
Dong-A ST Co., Ltd. (Licensing partner)Contract research organizationsClinical study investigators
ANA001 is a proprietary oral formulation of niclosamide designed to leverage the anti-viral and anti-inflammatory properties of the drug to treat patients suffering from moderate cases of COVID-19.
Price Range: N/A (Pipeline asset)
Pain Points: Clinical management of moderate COVID-19 symptoms.
Solutions: Oral delivery of an anti-viral agent to manage infection severity.
Target Users: Patients with moderate COVID-19.
Supply Chain
Pharmaceutical raw material suppliersDrug formulation partners
NB-01 is a therapeutic asset within MetaVia's portfolio aimed at mitigating the chronic pain associated with diabetic neuropathy.
Price Range: N/A (Pipeline asset)
Pain Points: Chronic nerve pain caused by diabetes.
Solutions: Symptom relief for neuropathic pain.
Target Users: Diabetic patients suffering from peripheral neuropathy.
Supply Chain
Internal development and research partners
NB-02 is in the MetaVia pipeline focused on therapeutic intervention for conditions characterized by cognitive decline.
Price Range: N/A (Pipeline asset)
Pain Points: Loss of cognitive function and decline in mental capacity.
Solutions: Therapeutic potential for treating cognitive impairment.
Target Users: Patients experiencing cognitive decline or impairment.
Supply Chain
Internal development and research partners
Gemcabene is a lipid-regulating agent that the company licenses to Pfizer Inc. for further development and commercialization in the dyslipidemia space.
Price Range: N/A (Licensed asset)
Pain Points: High blood lipid levels and cardiovascular risk associated with dyslipidemia.
Solutions: Reduction of lipid levels in the blood.
Target Users: Patients with dyslipidemia or cardiovascular health risks.
